Data / Drug companies / Reese Pharmaceutical Co
Reese Pharmaceutical Co: 13 products in the FDA NDC directory, labeler code 10956
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Reese Pharmaceutical Co (labeler code 10956) lists 13 products in the FDA National Drug Code Directory, covering 8 finished drugs by generic name. By type: 13 over the counter drugs. Its main marketing category is over the counter monograph drugs. The newest product started marketing on May 24, 2023.
The request: Watch Reese Pharmaceutical Co (FDA labeler code 10956): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 10956
- Products in commercial distribution
- 13
- Packages
- 18
- Finished drugs by generic name
- 8
- Prescription products
- 0
- Over the counter products
- 13
- Flagged as original packager
- 13 of 13 products that carry the flag
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- August 1, 2012
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Over the counter monograph drugs | 8 | 61.5% |
| Other unapproved drugs | 5 | 38.5% |
Products by type
| Type | Products | Share |
|---|---|---|
| Over the counter drugs | 13 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Phenazopyridine hydrochloride | 4 | 53 |
| Guaifenesin | 2 | 123 |
| Docusate sodium | 2 | 79 |
| Aspirin and caffeine | 1 | 10 |
| Pyrantel pamoate | 1 | 13 |
| Dextromethorphan hydrobromide / guaifenesin | 1 | 18 |
| Methenamine, sodium salicylate | 1 | 17 |
| Docusate calcium | 1 | 4 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 8 | 61.5% |
| Capsule, liquid filled | 3 | 23.1% |
| Powder | 1 | 7.7% |
| Suspension | 1 | 7.7% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Vexia Maximum Strength Urinary Pain Relief | 10956-703 | Tablet | Other unapproved drugs | May 24, 2023 |
| Preferred Stool Softener | 10956-891 | Capsule, liquid filled | Over the counter monograph drugs | May 11, 2023 |
| Preferred Stool Softener laxative | 10956-781 | Capsule, liquid filled | Over the counter monograph drugs | May 11, 2023 |
| Preferred Stool Softener | 10956-621 | Capsule, liquid filled | Over the counter monograph drugs | May 11, 2023 |
| Pinworm Medicine | 10956-778 | Suspension | Over the counter monograph drugs | September 28, 2022 |
| Refenesen Mucus Relief DM | 10956-846 | Tablet | Over the counter monograph drugs | April 15, 2021 |
| Refenesen Mucus Relief | 10956-845 | Tablet | Over the counter monograph drugs | April 15, 2021 |
| Reese Headache Powders | 10956-501 | Powder | Over the counter monograph drugs | July 22, 2020 |
| Preferred Maximum Strength Urinary Pain Relief | 10956-210 | Tablet | Other unapproved drugs | July 31, 2019 |
| Preferred Antibacterial Plus Urinary Pain Relief | 10956-763 | Tablet | Other unapproved drugs | February 22, 2017 |
| Preferred Urinary Pain Relief | 10956-551 | Tablet | Other unapproved drugs | July 1, 2013 |
| CVS Health Urinary Pain Relief | 10956-001 | Tablet | Other unapproved drugs | July 1, 2013 |
| DG Health Immediate Release Mucus Relief | 10956-059 | Tablet | Over the counter monograph drugs | August 1, 2012 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.